RRB NTPC Result News 2025 Live: Steps to check CBT 1 result for graduate posts when out
RRB NTPC CBT 1 Result 2025 News Live Updates 2025: Railway Recruitment Boards have not yet announced the results of the Non-Technical Popular Category (NTPC) graduate level posts recruitment examination. When declared, candidates can check their results on the official website of the regional RRBs where they applied. Previously, RRBs released the NTPC graduate exam's answer key and invited objections up to July 6 on the payment of ₹50 plus bank charges per question....Read More
RRBs said if an objection is found to be correct, the fee paid against it will be refunded.
RRB NTPC CBT 1 was held from June 5 to June 24, 2025.
The paper had 100 questions, each worth one mark. Negative marking was also used, and 1/3 marks would be deducted for every incorrect answer.
Candidates who qualify in CBT 1 will be shortlisted for CBT 2, which will be of objective type with multiple-choice questions. The duration for CBT 2 will be 90 minutes. For PwBD candidates, the duration will be 120 minutes.
Following CBT 2, RRBs will conduct Typing Skill Test/Computer Based Aptitude Test (as applicable) and Document Verification/Medical Examination.
This NTPC recruitment drive is for 8113 graduate-level posts. These include 1736 vacancies for Chief Commercial cum Ticket Supervisor, 994 vacancies for Station Master, 3144 vacancies for Goods Train Manager, 1507 vacancies for Junior Account Assistant cum Typist, and 732 vacancies for the Senior Clerk cum Typist post.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
2 hours ago
- NDTV
Want To Settle Abroad? Malta Is Offering A Permanent Residence Programme
If you want to live by the Mediterranean Sea, Malta is offering Permanent Residence Programme (MPRP) that allows non-EU citizens to get permanent residency in Malta through investment, offering benefits like living, working and studying in Malta. For this visa, you will have to combine property investment or rental with government contributions. Getting this visa also means that you will be allowed visa-free travel across the Schengen Area. Who Is Eligible All non-EU citizens, including Indians. People who are 18 years old or above. No criminal record. Either €500,000 (Rs 5,10,06,000 approx.) in total assets or €650,000 ( Rs 6,63,07,800 approx.) in total assets Financial Requirements You will need to buy a property for at least €3,75,000 (Rs 3,82,54,500 approx.) or rent a property for five years for €14,000 (Rs 14,28,168 approx.) per year. You may have to pay additional costs in the form of government contribution: €80,000 (Rs 81,60,960 approx.) and €110,000 (Rs 1,12,21,320 approx.) Documents Required A valid passport and completed application forms. Biometric data and passport-sized photographs. Proof of residential address. Bank statements and asset verification. Health insurance covering Malta. Police clearance certificate. Marriage or birth certificates (if applying with family). Certified English or Maltese translations and notarization of documents. Declaration of intent to reside permanently in Malta. How To Apply Gather and prepare all the documents mentioned above. Submit the application and pay €15,000 (Rs 15,30,180 approx.) fee. The Residency Malta Agency will conduct a thorough due diligence check which includes verifying your information. Once approved, you will have to fulfill the investment requirements. Make the investment, government contribution and NGO donation. You should receive your residency card within 6-12 months.
News18
3 hours ago
- News18
Alkem Q1 profit rises 22 pc to Rs 664 cr
Agency: PTI Last Updated: New Delhi, Aug 12 (PTI) Alkem Laboratories on Tuesday said its net profit increased 22 per cent year-on-year to Rs 664 crore during the June quarter. Total revenue from operations stood at Rs 3,371 crore with year-on-year growth of 11 per cent. 'Q1 FY26 marked a strong start to the year, with healthy growth across both our domestic and international markets," Alkem CEO Vikas Gupta said in a statement. The company's performance was driven by strong topline growth and an improved gross margin, which resulted in a better EBITDA profile, he added. 'We are strategically accelerating our focus on the non-US business segment by strengthening our presence in high-potential non-US markets and capturing new opportunities that align with our long-term growth ambitions," Gupta added. PTI MSS TRB First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
&w=3840&q=100)
Business Standard
4 hours ago
- Business Standard
Alkem Labs Q1 profit rises 22% to ₹664 cr on India, overseas sales growth
Alkem Laboratories on Tuesday reported a 22 per cent year-on-year (Y-o-Y) rise in its consolidated net profit for the June quarter (Q1FY26) to ₹664.3 crore, up from ₹545.2 crore in the same period last year. Revenue from operations increased 11.2 per cent Y-o-Y to ₹3,371 crore in Q1FY26 from ₹3,031 crore in Q1FY25. The company attributed this growth to strong sales in both India and international markets. Commenting on the performance, Vikas Gupta, Chief Executive Officer of Alkem, said Q1FY26 marked a strong start to the year, with healthy growth across both domestic and overseas markets. India sales grew 12 per cent Y-o-Y to ₹2,265 crore in the June quarter, while international sales rose 8.9 per cent to ₹1,054 crore, contributing 31.7 per cent to overall revenue. In the international business, the United States market recorded sales of ₹698 crore, up 8.8 per cent from ₹641.6 crore a year earlier, contributing 21 per cent to total sales. Sales from other international markets — including Latin America, Australia, and Europe — rose 9.1 per cent to ₹355.6 crore, contributing 10.7 per cent to revenue. Gupta said the company is strategically accelerating its focus on the non-US business segment by strengthening its presence in high-potential markets and capturing new opportunities aligned with Alkem's long-term growth ambitions. Alkem also announced it will incorporate a Saudi Arabia-based subsidiary, holding a 51 per cent stake. 'The subsidiary is proposed to be incorporated as a limited liability company and will be involved in the manufacture, import, marketing, and distribution of pharmaceutical and/or nutraceutical products within the Kingdom of Saudi Arabia,' the company said in a filing to the exchanges. On Tuesday, Alkem Laboratories' share price rose 6.7 per cent to close at ₹5,167 on the Bombay Stock Exchange (BSE).
